Resistance To Resistance

Fighting the silent pandemic through science & community

Research, education, and community engagement working together to make antimicrobial resistance easier to understand—and harder to ignore.

Viewing Understanding the Crisis
700K Deaths per year from drug-resistant infections globally
10M Projected annual deaths by 2050 if AMR goes unchecked
7 Research & outreach projects completed by Resistance To Resistance
5+ Physicians interviewed on frontline AMR perspectives
AMR — Antimicrobial Resistance

Fighting the silent pandemic through science & community

Resistance To Resistance brings together phage therapy research, physician perspectives, public health outreach, and youth education to combat one of medicine's most urgent crises.

Explore Research What is AMR?
700K Deaths per year from drug-resistant infections globally
10M Projected annual deaths by 2050 if AMR goes unchecked
7 Research & outreach projects completed by Resistance To Resistance
5+ Physicians interviewed on frontline AMR perspectives

Understanding the crisis

What is Antimicrobial Resistance?

Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi, and parasites evolve to defeat the drugs designed to kill them. When an infection becomes resistant, standard antibiotics stop working — making infections harder or impossible to treat.

AMR is not a future threat. It is happening right now in hospitals, farms, and communities around the world. Every unnecessary antibiotic prescription, every incomplete treatment course, and every antibiotic used in animal feed contributes to the problem.

Resistance To Resistance exists to raise awareness, publish research, educate communities, and train the next generation of AMR fighters — because awareness is the first step toward action.

Phage Therapy Research

Bacteriophages — viruses that infect and destroy bacteria — represent one of the most promising frontiers in the fight against drug-resistant infections.

Physician Perspectives

Real doctors on the frontline share how AMR is changing clinical decision-making and what must change in prescribing culture.

Community Outreach

Taking AMR education beyond the lab — to farmer's markets, schools, and public health fairs where the message matters most.

AMR at a glance

Why antimicrobial resistance demands attention

A concise snapshot of the burden of bacterial antimicrobial resistance. Explore the full data, science, prevention guidance, and Resistance To Resistance projects below.

WHO · 20231 in 6

laboratory-confirmed bacterial infections causing common illnesses worldwide was resistant to antibiotic treatment.

Global · 20214.71M

deaths were associated with bacterial antimicrobial resistance.

Global · 20211.14M

deaths were attributable to bacterial resistance itself.

Projected · 20501.91M

deaths attributable to bacterial AMR under the study reference scenario.

Learn about AMR

Choose a topic to explore

Global surveillance & future burden

AMR by the Numbers

Data reviewed September 2026. The global figures below focus on antibiotic resistance in bacteria, one part of the broader antimicrobial resistance (AMR) problem.

Evidence snapshot 2026
WHO · 2023 1 in 6

laboratory-confirmed bacterial infections causing common illnesses worldwide was resistant to antibiotic treatment.

Global · 2021 4.71M

deaths were associated with bacterial antimicrobial resistance.

Global · 2021 1.14M

deaths were attributable to bacterial resistance itself.

Projected · 2050 1.91M

deaths attributable to bacterial AMR under the reference scenario.

01

What the latest surveillance shows

In 2023, approximately 1 in 6 laboratory-confirmed bacterial infections causing common illnesses worldwide was resistant to antibiotic treatment, according to the World Health Organization (WHO). Its 2025 surveillance report analyzed more than 23 million confirmed cases reported across multiple years. Resistance varied by region: WHO estimated that about 1 in 3 reported infections was resistant in its South-East Asia and Eastern Mediterranean regions, compared with 1 in 5 in its African region.

The trend is also concerning. From 2018 to 2023, resistance increased in more than 40% of the bacteria–antibiotic combinations WHO monitored for trends. Among those combinations, the average annual increase was 5% to 15%. These figures describe infections tested and reported through surveillance systems; they do not mean that one in six people worldwide has a resistant infection.

02

The human toll

A global study published in The Lancet estimated that bacterial AMR was associated with 4.71 million deaths in 2021. Within that total, 1.14 million deaths were attributable to resistance itself: the estimated additional deaths compared with a situation in which those infections had responded to antibiotics. These are modeled estimates, and the distinction matters when interpreting the numbers.

In the United States, the CDC’s 2019 national report estimated more than 2.8 million resistant infections and more than 35,000 resulting deaths each year. That remains a widely used national estimate, but it is an older baseline. A newer CDC update found that six types of resistant infections beginning in hospitals rose by a combined 20% during the COVID-19 pandemic; their rates remained above pre-pandemic levels in 2022.

Associated deaths · 20214.71MGlobal bacterial AMR
Attributable deaths · 20211.14MGlobal bacterial AMR
03

What could happen by 2050?

The Lancet study projects that, under its reference scenario, deaths attributable to bacterial AMR could reach 1.91 million in 2050, with 8.22 million deaths associated with resistant infections that year. Across 2025–2050, the researchers project roughly 39 million cumulative deaths attributable to bacterial AMR. That is a total over 26 years, not a prediction for one year.

These are forecasts, not fixed outcomes. Preventing infections, improving access to testing and effective treatment, using antibiotics appropriately, and developing new medicines can change the course of AMR.

Mechanisms · selection · spread

The Science of Antimicrobial Resistance

Antimicrobial resistance (AMR) occurs when germs survive medicines designed to stop them. It can affect bacteria, fungi, viruses, and parasites. This section uses antibiotic-resistant bacteria to explain the science behind it.

Science overview AMR

Understanding AMR requires following what happens at the level of the microbe. Antibiotics are powerful tools, but when bacteria carry or acquire traits that let them survive exposure, treatment becomes harder, infections can last longer, and resistant strains have more opportunities to spread.

This does not mean the person becomes resistant. The resistance develops in the bacteria themselves, then becomes more common through selection and gene transfer.

How resistance begins

Antibiotics kill bacteria or stop them from growing by disrupting essential processes, such as building a cell wall. However, some bacteria already carry a trait that helps them survive a particular antibiotic. That trait may arise through a change in their DNA or through a resistance gene acquired from another bacterium.

Illustration showing how antibiotic resistance develops in four stages, from a mixed bacterial population to survival and spread of resistant bacteria.
How antibiotic resistance develops. Antibiotic exposure leaves resistant bacteria with an opportunity to survive, multiply, and share resistance traits. Source: CDC.

When an antibiotic is used, susceptible bacteria are removed while bacteria with an effective resistance trait may survive. The survivors can multiply, making that trait more common. This is natural selection. Antibiotic use creates this pressure even when treatment is necessary; unnecessary use adds pressure without providing a medical benefit.

Resistance develops in the bacteria, not in the person taking the antibiotic.

Natural selection DNA change Gene acquisition Selection pressure

How bacteria defeat an antibiotic

For an antibiotic to work, it must reach its target and remain active. Resistant bacteria can interfere with that process in several ways:

Destroy the drug

Some bacteria produce enzymes that break down an antibiotic.

Keep the drug out

Changes to the cell’s outer layers can limit how much medicine enters.

Pump the drug out

Proteins in the cell membrane can remove an antibiotic before enough accumulates.

Change the target

An altered target may prevent the antibiotic from attaching and doing its job.

Work around the target

A bacterium may use a different cellular pathway to survive despite the drug.

Scientific illustration of a bacterium showing multiple antibiotic resistance mechanisms, including reduced drug entry, drug breakdown, efflux, target changes, and alternative pathways.

A bacterium can carry more than one defense. Resistance to one antibiotic also does not automatically mean resistance to every antibiotic.

Close-up scientific illustration of a resistant bacterium and several cellular defenses against antibiotics.

How resistance spreads

When a resistant bacterium reproduces, it passes its resistance traits to its descendants. Bacteria can also acquire genes from other bacteria. Some resistance genes travel on plasmids, small circles of DNA that can move between cells. Bacteria may also pick up DNA released into their surroundings. In some cases, bacteriophages—viruses that infect bacteria—carry bacterial DNA from one cell to another.

Resistant bacteria can then spread between people and through healthcare settings, food, animals, and the environment. A person can develop a resistant infection even if they have never taken the antibiotic to which the bacteria are resistant.

What this science tells us

Doctors can use diagnostic and antibiotic susceptibility tests, when appropriate, to learn which treatment is likely to work. Using antibiotics only when needed and taking them exactly as prescribed helps limit avoidable selection pressure. Preventing infections through measures such as handwashing and vaccination reduces opportunities for resistant bacteria to spread.

Sources Evidence behind this section
CDC overview of AMR CDC guide to gene transfer WHO AMR fact sheet

Prevention · stewardship · community action

Preventing AMR Starts Where We Live

Small daily choices and supportive communities can help slow antimicrobial resistance (AMR). Preventing infections reduces the need for treatment. Using antimicrobial medicines appropriately when they are needed helps protect their effectiveness.

Everyday action AMR
✓

Prevention works on two fronts: reduce the number of infections that need treatment, and use antimicrobial medicines appropriately when treatment is needed. CDC prevention guidance.

What individuals can do

01
Prevent infections.

Wash your hands with soap, prepare food safely, and ask which vaccines are recommended for you.

02
Ask what treatment fits your illness.

Antibiotics treat certain bacterial infections, but they do not treat viruses such as those that cause colds or flu. If you do not need an antibiotic, ask how to relieve symptoms and when to seek further care.

03
Follow your prescription.

Take antibiotics and antifungals exactly as prescribed. Contact your clinician or pharmacist with questions or concerns.

04
Keep prescriptions personal.

Do not share antibiotics or use saved leftovers for a later illness.

What communities can do

Schools, shelters, food banks, workplaces, and healthcare partners can make prevention and timely care easier to access:

01
Equip shared spaces.

Provide clean water, soap, handwashing supplies, and sanitation.

02
Connect people to care.

Link people with local clinics, pharmacies, and public health teams that can provide vaccination, assessment, and appropriate treatment.

03
Share usable information.

Use plain language and relevant languages through trusted community partners.

04
Support safer healthcare.

Strengthen infection prevention and careful antimicrobial use.

Start locally

Begin where people already gather.

Choose a place where people already gather. Check whether handwashing supplies are reliably available, share an accessible AMR resource, and ask visitors what makes prevention or timely care difficult.

Public health outreach

Community Outreach for AMR Awareness

Taking AMR awareness directly into the community through conversations, educational materials, outreach kits, and public events.

Community moments

AMR awareness in action

01 / 25

Published research

Bacteriophage Therapy: A Double-Edged Sword in Modern Medicine

Researcher conducting laboratory work at a laboratory bench
Behind the Research
From laboratory investigation to clinical possibility

Exploring bacteriophage therapy as a potential tool against antimicrobial resistance.

Click image to replace
International Journal of High School Research publication page for Bacteriophage Therapy: A Double-Edged Sword in Modern Medicine
Published · 2026
International Journal of High School Research
DOI Link ↗
Click image to replace
Topic 1 · Review article

Can viruses help solve the growing problem of antibiotic resistance?

As antibiotic-resistant infections become increasingly difficult to treat, researchers are revisiting an unusual alternative: bacteriophages, viruses that specifically infect bacteria. This research explores whether phage therapy could complement or, in some cases, provide an alternative to conventional antibiotics.

About the Research

This review article examines the benefits, limitations, and clinical potential of bacteriophage therapy, with a particular focus on its role in combating antimicrobial resistance. The study considers how phages work, their advantages over conventional antibiotics, challenges to their clinical use, results from recent human studies, and current attitudes toward phage therapy.

For the clinical portion of the review, 368 articles were initially identified across PubMed, ScienceDirect, and ClinicalTrials.gov, with 10 recent human studies ultimately selected for detailed analysis. Eight were clinical trials and two were individual case reports.

368 articles initially identified
10 human studies analyzed in depth
8 clinical trials selected
2 individual case reports reviewed

What Did the Research Find?

Phage therapy shows several promising characteristics. Bacteriophages can target specific bacteria, replicate at infection sites, attack some biofilm-associated infections, and potentially work alongside antibiotics. Recent clinical studies reviewed in the paper generally reported favorable safety profiles, particularly in difficult-to-treat or drug-resistant infections.

At the same time, phage therapy remains a developing field. Matching the correct phage to a patient's bacterial strain can be difficult, treatment formulations vary considerably, and questions remain about dosing, immune responses, bacterial resistance to phages, manufacturing, and regulation. The review concludes that greater standardization and larger clinical studies are needed before phage therapy can become widely used.

Promising Features
  • Precise targeting of specific bacteria
  • Self-replication at infection sites
  • Potential activity against certain biofilms
  • Possible synergy with antibiotics
  • Generally favorable safety findings in recent studies
Remaining Challenges
  • Difficult matching of phages to bacterial strains
  • Wide variation in treatment formulations
  • Unresolved dosing and immune-response questions
  • Possible bacterial resistance to phages
  • Manufacturing and regulatory hurdles

Why It Matters

The same feature that makes bacteriophages exciting—their ability to precisely target particular bacteria—also makes them challenging to turn into standardized medicines. That “double-edged sword” is at the center of the paper: phage therapy has substantial potential against antibiotic-resistant infections, but realizing that potential will require overcoming scientific, logistical, and regulatory barriers.

Precision is both phage therapy’s greatest strength and one of its biggest barriers to standardization.

Publication

Bacteriophage Therapy: A Double-Edged Sword in Modern Medicine

AuthorAnanya Anand
JournalInternational Journal of High School Research, 2026
TypeReview Article
AwardsRecognition for AMR research, presentation, and public-health impact

Academic achievement

Illinois State University Presentation

🥉
3rd Place — Research Presentation Award Illinois State University — AMR Research Category

Resistance To Resistance's research on phage therapy and antimicrobial resistance was presented at Illinois State University, earning 3rd place in the research presentation competition — a testament to the scientific rigor and real-world relevance of this work.

The presentation covered the scope of the global AMR crisis, the science of bacteriophage therapy, original research findings, and a roadmap for community-level action. The panel of academic and medical judges recognized the work's combination of research depth and public health impact.

This achievement highlights the growing recognition of phage therapy research within academic communities and validates Resistance To Resistance's mission to bridge laboratory science with everyday community education.

Illinois State University research presentation highlights

Research discussion at Illinois State University
Discussing AMR research with symposium attendees•
AMR research presentation at Illinois State University
Presenting bacteriophage therapy research•
Recognition at Illinois State at Illinois State University
Recognized for research at Illinois State University•
Award ceremony at Illinois State University
Award ceremony at the Illinois State symposium•
Physicians' PerspectivesFrontline physician interviews and expert perspectives on antimicrobial resistance

Expert perspectives

Physicians' Perspectives

Physicians from across medical specialties share their frontline perspectives on the growing threat of antimicrobial resistance and what needs to change. Add up to three YouTube interview links and three supporting images below.

Dr

General Physician

General Physician AMR interview video thumbnail
Watch the interview General Physician · Antimicrobial Resistance
Dr

Pediatrician

Pediatrician AMR interview video thumbnail
Watch the interview Pediatrician · Antimicrobial Resistance
Dr

Palliative Care Physician

Palliative Care Physician AMR interview video thumbnail
Watch the interview Palliative Care Physician · Antimicrobial Resistance
Physician interview discussion
Physician InterviewClinical perspectives on antimicrobial resistance
One-on-one physician interview
One-on-One ConversationFrontline insight into responsible antibiotic use